Thiogenesis Therapeutics, Corp. (TSXV:TTI)
Canada flag Canada · Delayed Price · Currency is CAD
0.8200
+0.0300 (3.80%)
Jul 22, 2025, 4:00 PM EDT

Thiogenesis Therapeutics Company Description

Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs.

Its lead product candidate is TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and rett syndrome.

The company is headquartered in Toronto, Canada.

Thiogenesis Therapeutics, Corp.
CountryCanada
IndustryBiotechnology
SectorHealthcare
CEOPatrice Rioux

Contact Details

Address:
4 King Street West
Toronto, Ontario M5H 1B6
Canada
Phone888-223-9165
Websitethiogenesis.com

Stock Details

Ticker SymbolTTI
ExchangeTSX Venture Exchange
Fiscal YearJanuary - December
Reporting CurrencyCAD
SIC Code2836

Key Executives

NamePosition
Dr. Patrice P. Rioux M.D., Ph.D.Co-Founder, Chief Executive Officer and Director
Brook G. Riggins C.F.A.Chief Financial Officer, Secretary and Director
Mary Jo BaggerConsultant for Clinical Operations